Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GPC Biotech AG has unveiled new data on its lead drug candidate, satraplatin, revealing it to be active in drug-resistant tumor cells and to demonstrate a synergistic effect when used with Sanofi-Aventis' Taxotere.
Subscribe to our email newsletter
A poster presentation at the 96th annual meeting of the American Association for Cancer Research (AACR) in California, reviewed the results of a study designed to explore the activity of satraplatin in several drug-resistant human tumor cell lines, including those resistant to taxanes, mitoxantrone, etoposide, camptothecin and cisplatin.
The study results showed that the pre-treated cells remained sensitive to satraplatin, thereby providing a rationale for evaluation of satraplatin in patients who have progressed on these other cancer treatments.
In addition, researchers evaluated the effect of a combination of Taxotere (docetaxel) and satraplatin on prostate cancer cells. The results indicated that, when these cells are exposed first to Taxotere and then to satraplatin, there appears to be a synergistic effect. When the cells were exposed to the two compounds at the same time, only an additive effect was observed.
The results are supportive of studying a combination treatment of Taxotere and satraplatin in human clinical studies, including evaluating sequential regimens. GPC Biotech plans to initiate a phase I trial evaluating a combination treatment of satraplatin and Taxotere in the next few months.